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Abstract: Feae’s viper Azemipos feae belongs to the Azemiopinae subfamily of the Viperidae family.
The effects of Viperidae venoms are mostly coagulopathic with limited neurotoxicity manifested by
phospholipases A2. From A. feae venom, we have earlier isolated azemiopsin, a novel neurotoxin
inhibiting the nicotinic acetylcholine receptor. To characterize other A. feae toxins, we applied
label-free quantitative proteomics, which revealed 120 unique proteins, the most abundant being serine
proteinases and phospholipases A2. In total, toxins representing 14 families were identified, among
which bradykinin-potentiating peptides with unique amino acid sequences possessed biological
activity in vivo. The proteomic analysis revealed also basal (commonly known as non-conventional)
three-finger toxins belonging to the group of those possessing neurotoxic activity. This is the first
indication of the presence of three-finger neurotoxins in viper venom. In parallel, the transcriptomic
analysis of venom gland performed by Illumina next-generation sequencing further revealed 206
putative venom transcripts. Together, the study unveiled the venom proteome and venom gland
transciptome of A. feae, which in general resemble those of other snakes from the Viperidae family.
However, new toxins not found earlier in viper venom and including three-finger toxins and unusual
bradykinin-potentiating peptides were discovered.
Keywords: Feae’s viper; Azemiops feae; venom; venom gland; proteomics; transcriptomic;
bradykinin-potentiating peptides; three-finger toxins
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1. Introduction
Snake venoms are complex mixtures of peptides and proteins that are evolved in the process of
evolution for protection from predators and for hunting. Two major action strategies can be traced in
the venoms: a paralytic one inherent predominantly to elapids and colubrids and a coagulopathic
one inherent mostly to viperids. To date, it has been established that, despite the huge variety of
toxins, they can all be attributed to a limited number of families either possessing enzymatic activities
(e.g., phospholipases A2 (PLA2), snake venom serine proteases (SVSP), snake venom metalloproteinases
(SVMP)) or without such activities (e.g., lectins, three-finger toxins (3FTx), Kunitz-type inhibitors,
natriuretic peptides). The variation in the composition of venoms occurs at all taxonomic levels [1],
but the most drastic differences are evident at the level of families and subfamilies. As coagulopathies
are induced mostly through an enzymatic pathway, in general, enzymes are the main components of
viperid venoms. Paralytic effects, on the other hand, are produced more often by proteins without
enzymatic activity (e.g., three-finger neurotoxins), albeit non-enzymatic proteins are not the main
components in all elapid venoms. For example, in krait Bungarus fasciatus venom, PLA2 enzymes
comprise about 70% of all venom proteins [2]. Although traditional methods for characterization of
venoms based on chromatographic separation are still in use, the modern proteomic approaches yield
more detailed and complete information. The proteomes of about two hundred snake species have been
characterized so far [3,4], more than half of them (about 100 species) from viperids. Viperids (Viperidae
family) are divided into two major subfamilies, the Viperinae (Old World or pitless vipers) and the
Crotalinae (pit vipers). One more taxon, Azemiopinae, is recognized within the Viperidae; recent data
confirm Azemiopinae as the sister group of the Crotalinae [5,6]. Nowadays, Azemiopinae include the
genus Azemiops, the species composition of which is currently the subject of discussion. Recently,
in addition to the well-established Azemiops feae species, a new one Azemiops kharini was included in
the genus [7]. However, new data indicate that they are rather one species [8].
Data about venom composition for these fairly rare snakes are limited and available for A. feae
only. Earlier investigation of the enzymatic activity of this venom showed that it had no blood
clotting, hemorrhagic, or myolytic activities [9]. Recent studies confirmed the absence of coagulopathic
effects for A. feae venom [10]. In another study, PLA2 and plasminogen activator homologs were
found in the venom [11]. Three PLA2s were isolated from A. feae venom, and two of them contained
Asn49 in their active center and were catalytically inactive [12]. cDNAs encoding cysteine-rich
secretory protein (CRISP) [12], natriuretic-peptide precursors [13] and 3Ftx [14] were cloned from
A. feae. However, there are no data about the presence of the corresponding proteins in A. feae venom.
At the same time, natriuretic-peptide precursors contain sequences of a unique peptide neurotoxin,
which was isolated by us from the venom and called azemiopsin [15]. Azemiopsin is a primitive
neurotoxin; it consists of 21 residues and does not contain cysteine residues. By its capacity to block
the nicotinic acetylcholine receptor, azemiopsin resembles waglerin, a disulfide-containing peptide
from the Tropedolaemus wagleri venom, shares with it a homologous C-terminal hexapeptide and may
be considered as a waglerin ancestor. These peptide neurotoxins are not typical for Viperidae venom.
To find out what the other components are, we have analyzed A. feae venom in more depth using
high-throughput proteomics. In parallel, the transcriptomic analysis of venom gland was performed
by Illumina next-generation sequencing (NGS). About 70 toxins representing 14 toxins families were
identified; among them, new toxins not found earlier in viper venom and including three-finger toxins
and unusual bradykinin-potentiating peptides were discovered.
2. Experimental Section
2.1. Specimen Collection and Tissue Preparation
Specimen of A. feae was collected in Vinh Phuc Province, Vietnam. Venom gland was dissected 3
days after stimulation by milking and treated with RNAlater (Ambion, Thermo Fisher Scientific Inc,
Waltham, MA, USA) as described by the vendor.
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2.2. cDNA Library Preparation and Sequencing
For RNA extraction, venom gland dissected from one specimen of A. feae viper and stored in
RNAlater (Ambion, Thermo Fisher Scientific Inc, Waltham, MA, USA) was used. Total RNA was
isolated from the tissue sample by TRIzol kit (Invitrogen, Thermo Fisher Scientific Inc, Waltham, MA,
USA), and its quality was assessed on an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara,
CA, USA).
2.2.1. cDNA Synthesis and cDNA Amplification
For ds cDNA synthesis, the SMART approach [16] was applied. SMART-prepared cDNA was
amplified by PCR. Primer annealing mixture (5 µL) containing 0.3 µg of total RNA; 10 pmol of SMART
Oligo II oligonucleotide (5′-AAGCAGTGGTATCAACGCAGAGTACGCrGrGrG-3′) and 10 pmol of
CDS-T22 primer (5′-AAGCAGTGGTATCAACGCAGAGTTTTTGTTTTTTTCTTTTTTTTTTVN-3′) was
prepared, incubated for 2 min at 72 ◦C and was kept for 2 min on ice. The annealed primer-RNA
was mixed with Reverse Transcriptase in a final volume of 10 µL, containing 1X First-Strand Buffer
(50 mM Tris-HCl (pH 8.3); 75 mM KCl; 6 mM MgCl2), 2 mM DTT and 1 mM of each dNTP to
start the first-strand cDNA synthesis. This reaction mixture was maintained at 42 ◦C for 2 h in a
thermostat and then cooled on ice. After dilution by 5 times with TE buffer, the first-strand cDNA
was incubated for 7 min at 70 ◦C and then was amplified by Long-Distance PCR (Barnes, 1994).
PCR reaction mixture (50 µL) contained 1 µL diluted first-strand cDNA, 1 µL 50× Advantage reaction
buffer (Clontech, Takara Bio, Mountain View, CA, USA), 200 µM dNTPs; 0.3 µM SMART PCR primer
(5′-AAGCAGTGGTATCAACGCAGAGT-3′) and 1 µL 50× Advantage Polymerize mix (Clontech,
Takara Bio, Mountain View, CA, USA). PCR was performed on MJ Research PTC-200 DNA Thermal
Cycler under the following program: 95 ◦C −7 s, 65 ◦C −20 s, 72 ◦C −3 min, 17 cycles. Amplified cDNA
PCR product was purified using QIAquick PCR Purification Kit (Qiagen, Venlo, Netherlands).
2.2.2. Illumina Sequencing
The standard Illumina protocol was applied to prepare libraries for DNA using TruSeq Illumina
DNA sample preparation kit. NGS was performed on Illumina Genome Analyzer IIx in the paired-end
sequencing mode (2 × 72 bp).
2.3. NGS Data Analysis
Sequenced data from Illumina GAIIx were transformed by base calling into sequence data, called
the raw data or raw reads, and were stored in FASTQ format. For quality control checks on raw sequence
data, we used FastQC (version 0.11.5). Trimmomatic (version 0.38) was applied to trim the adapter
sequences used for cDNA synthesis. For de novo transcriptome assembly, we used Trinity software
(version r20131110) with the default settings. Contigs from Trinity were translated using all six reading
frames to obtain “Predicted protein SET 1”. Local BLAST (BlastX threshold value of e = 1 × 10−6,
matrix BLOSUM-62) and the non-redundant database were used for the grouping and annotation
of contigs. Blast2GO (version 5.2.1) was used for Taxonomy, Gene Ontology (GO) and EuKaryotic
Orthologous Groups (KOG) analysis for functional annotation of contigs. TransDecoder was applied
to identify putative ORFs with a minimum length of 100 amino acids. The ORF database (10997
sequences) generated with Transdecoder called “Predicted protein SET 2” was used for proteomics.
2.4. Other Computational Tool
Translation of transcriptome sequences in all 6 frames to amino acid sequences was done with
Nucleotide Sequence Translation EMBOSS Transeq/EMBOSS Sixpack. The ORF database (120510
sequences) generated with EMBOSS Sixpack was used for proteomics. Prinseq lite v.0.20.4 was used for
reads quality and length trimming. ClustalW2 and MUSCLE algorithms integrated into package Jalview
v.2.11.1.0 were used to perform multiple alignment construction and visualization [17]. For calculating
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expression levels (Transcripts Per Kilobase Million (TPM) and Reads Per Kilobase Million (RPKM), we
used CLC Genomic Workbench 10 (Qiagen, Venlo, Netherlands) with the default settings.
2.5. BioProject and Raw Sequence Data
Sequence data from the venom gland transcriptome of the A. feae have been deposited in National
Centre for Biotechnology Information (NCBI) Sequence Read Archive with the accession number
SRR8177476 under Bioproject PRJNA504599.
2.6. Reduction, Alkylation and Digestion of the Proteins
The proteins were reduced, alkylated and digested as described previously [18] with small
variations. In brief, to a venom sample (10 µg), sodium deoxycholate (SDC) buffer (pH 8.5) for
reduction and alkylation was added so as to achieve the final concentration of proteins, Tris, SDC,
tris(2-carboxyethyl)phosphine and 2-chloroacetamide of 0.5 mg/mL, 100 mM, 1% (w/v), 10 mM and
20 mM, respectively. The reaction mixture was incubated at 95 ◦C for 10 min and cooled to ambient
temperature. Digestion with trypsin (solution in equal volume of 100 mM Tris, pH 8.5) at a 1:100 (w/w)
ratio was performed at 37 ◦C overnight.
2.7. Tryptic Peptides Desalting
Peptides were desalted with application of SDB-RPS StageTips, which were made as previously
described [19]. In brief, two small portions of the 3M Empore SDB-RPS membrane were cut with a
blunt-tipped Hamilton needle (part no. 91014: gauge 14, type Point 3, metal (N) hub) and pressed into
the 200-µL pipette tip using 1/16 PEEK tubing (1535, Upchurch Scientific, Thermo Fisher Scientific
Inc, Waltham, MA, USA). As a StageTip holder, 2 mL microcentrifuge tube with a hole punched in the
cap (O-tube) was used. O-tube and SDB-RPS StageTip composed a Spin block. An equal volume of
2% (v/v) TFA was added to the tryptic peptide solution obtained after overnight hydrolysis, and the
solution thus obtained was applied to StageTip using centrifugation at 200 g. StageTip was cleaned
by washing first with mixture of 50 µL ethylacetate with 50 µL 1% (v/v) TFA (3 times), then 50 µL 1%
(v/v) TFA and finally 50 µL 0.2% (v/v) TFA. The elution of peptides was achieved by application of
60 µL 50% (v/v) acetonitrile containing 5% (v/v) NH4OH; the eluted peptides were freeze-dried and
preserved at −80 ◦C. For further analysis, peptides were dissolved in 20 µL of 2% (v/v) acetonitrile
containing 0.1% (v/v) TFA and treated with ultrasound for 2 min.
2.8. Liquid Chromatography and Mass Spectrometry
The column (25 cm with inner diameter of 75 µm) in-house packed with Aeris Peptide XB-C18 2.6
µm resin (Phenomenex, Torrance, CA, USA) was applied for the separation of peptides. An Ultimate
3000 Nano LC System (Thermo Fisher Scientific Inc, Waltham, MA, USA) was used for reverse-phase
chromatography. The LC System was connected through a nanoelectrospray source (Thermo Fisher
Scientific) to a Q Exactive HF mass spectrometer (Thermo Fisher Scientific). A linear 120-min gradient
of 4–55% solvent B (80% (v/v) acetonitrile containing 0.1% (v/v) formic acid was used for the elution of
peptides at a flow rate of 350 nL/min (40 ◦C). TopN method with an automatic switch between a full
scan and up to 15 data-dependent MS/MS scans was applied for MS data acquisition. The target value
of 3 × 106 in the 300–1200 m/z range with a resolution of 60,000 and a maximum injection time of 60 ms
was used for the full-scan MS spectra. A 1.4 m/z window and a fixed first mass of 100.0 m/z was used
to perform isolation of precursors. A higher-energy dissociation (HCD) and a normalized collision
energy of 28 eV were applied for fragmentation of precursors. An ion target value of 1 × 105 in the
200–2000 m/z range with a resolution of 15,000 at m/z 400 and a maximum injection time of 30 ms were
used for the acquisition of MS/MS scans. Six technical replicates were performed to analyze the sample
by LC–MS/MS.
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2.9. Data Analysis
Six technical replicates were used for MS measurements of venom sample. MS/MS-based
qualitative proteome analysis of venom proteins was made using PEAKS Studio 8.0 build 20160908
software [20]. Peptide lists generated by the PEAKS Studio were searched against the “SET 2”
FASTA database. Carbamidomethylation was set as a fixed modification for cysteine and acetylation
for N-terminus, oxidations for methionine and deamidations for asparagine were set as variable
modifications and specificity of protease was set to semitryptic. For peptide-spectrum matches, the
false discovery rate (FDR) was fixed to 0.01 and the search of a reverse database was used to determine
FDR. An allowed fragment mass deviation of 0.05 Da and an allowed initial precursor mass deviation
up to 10 ppm were used to perform the peptide identification. If at least 1 unique peptide was found
for a protein, it was regarded as identified reliably. MaxQuant program version 1.5.6.5 [21] was
applied for label-free protein quantification. Carbamidomethylation was set as a fixed modification for
cysteine and acetylation for N-terminus, oxidations for methionine and deamidations for asparagine
were set as variable modifications and specificity of protease was set to semitryptic. The Andromeda
search engine [22] was used for the search of peak lists against the “SET 1” FASTA database and a
common contaminant database implemented in the search engine. The FDR of 0.01 was fixed for
both proteins and peptides, and a minimum length of seven amino acids was used. An allowed
fragment mass deviation of 20 ppm and an allowed initial precursor mass deviation up to 20 ppm were
used to perform the peptide identification. Perseus (versions 1.5.5.1) [23] was applied to perform the
downstream bioinformatics analysis. From the analyses were excluded groups of proteins which were
identified only by site, from peptides identified also only in the reverse database oring belonged to the
database of common contaminant. A minimum ratio count of 1 was applied to perform the label-free
quantification. The iBAQ algorithm, implemented into the MaxQuant program [21], was used to
quantify proteins in the venom sample. To generate a relative iBAQ (riBAQ) value representing the
mole fraction of each protein [24], normalization of each protein’s iBAQ value against the sum of all
iBAQ values was performed.
2.10. Characterization of Bradykinin-Potentiating Peptides by MALDI Mass Spectrometry
De novo peptide sequencing was performed by matrix-assisted laser desorption ionization-time
of flight mass spectrometry (MALDI-TOF-MS/MS) using an Ultraflex-II TOF/TOF instrument (Bruker
Daltonics, Bremen, Germany) equipped with a 200 Hz solid-state Smart beam™ laser.
HPLC-purified samples were applied using α-cyano-4-hydroxycinnamic acid (CHCA, saturated
solution in 33% acetonitrile/0.1% trifluoroacetic acid) onto a polished-steel target. The instrument
was operated in positive reflector mode and MS/MS spectra generated by spontaneous post-source
decay were recorded using the LIFT cell technology [25]. The fragment spectra were interpreted and
labeled manually.
2.11. Peptide Synthesis
The bradykinin-potentiating peptides (BPP) were prepared by peptide synthesis and purified by
reverse-phase chromatography as described [26].
2.12. Blood Pressure Measurements
The experiments were carried out on adult male Sprague-Dawley (SD) rats (300–350 g of body
weight). The World Health Organization’s International Guiding Principles for Biomedical Research
Involving Animals were followed during experiments on animals. The experiments were approved
by the Institutional Animal Care and Use Committee (IACUC No.536/18). Four groups of 6 rats in
each were used for the study. Before the experiment, catheters were implanted into the jugular vein
and carotid artery of rats under anesthesia (Zoletil-100 at a dose of 20 mg/kg and Rometar at a dose of
12 mg/kg). The arterial catheter was used to record blood pressure (mean BP) and the venous catheter
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for injection of test drugs (Y-BPP or R-BPP). Blood pressure parameters were recorded on conscious
animals a day after surgery (to allow for recovery of the animals from anesthesia) continuously using
a strain gauge pressure transducer linked to Powerlab ML125 system (AD Instrument, Australia).
After 10 min of recording of baseline parameters, bradykinin was introduced (1st injection, 7 µg/kg);
10 min after bradykinin, for the experimental group, BPP (Y-BPP or R-BPP in two doses: 300 µg/kg
or 1 mg/kg) was introduced (2nd injection). Then, on the 5th minute after BPP injection, bradykinin
(7 µg/kg, 3rd introduction) was again introduced; on the 50th minute after beginning of the experiment,
bradykinin was again given at the same dose (4th introduction). The last introduction of bradykinin
was at the 80th minute (5th introduction). Data were then analyzed and mean BP ± SEM calculated.
All quantitative data are presented as mean ± SD. Statistical analysis was performed by software
Statistica for Window v.7.1 to compare the treated groups. Significance level was determined at p ≤ 0.05.
No rats or data points were excluded from the reported analyses.
3. Results
3.1. Research Outline: RNA Sequencing and Analysis of the Initial Data
To perform a comprehensive analysis of Feae’s viper A. feae venom, we used two complementary
approaches (Figure 1). To study proteins and peptides present in the venom, quantitative proteomics
was applied (Table S1), while the transcriptome of the venom gland was analyzed by NGS.
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eu aryote rthologous roups, TAP Animal Toxin Annotation Project (UniProt).
From the venom glands of A. feae, we generated 29,055,985 pairs of 75 bp reads that passed the
Illumina filter (Table S2). Basic filters recommended for qualitative analysis of Illumina were applied
to the raw reads, and the adapters used for cDNA synthesis were trimmed. Final cDNA short reads
dataset was used for the de novo assembly of a transcriptome using the Trinity assembler. Trinity
created 20,085 contigs (reconstructed transcripts) with (N50 = 781), connected to form 18,296 “genes”
in total assembly statistics (Table S3).
Next, the gene ontology (GO), eukaryotic orthologous groups (KOG) and taxonomic affiliation of
the contigs were analyzed using the Blast2GO program and the BlastX algorithm. The non-redundant
database served as a reference database (Figures S1–S3). Furthermore, for identifying potential toxins
in the transcriptome, local BlastX was used. As a reference database, we used all toxin sequences from
the UniProt animal toxin annotation project (https://www.uniprot.org/program/Toxins). As a result,
206 putative venom transcripts clustered into 112 groups were identified (Table S4).
Finally, all contigs from Trinity were translated using all six reading frames in “Predicted protein
SET 1” for subsequent validation by proteomics. The prediction of coding regions (or open read frames,
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ORFs) and annotation of transcriptomic data were carried out using Transdecoder and Trinotate.
In addition, ORFs from Transdecoder were translated in “Predicted protein SET 2” for subsequent
validation by proteomics. Both data sets were used to analyze the total proteome using the PEAKS
Studio software. Transcriptome database was used for the quantitative analysis search in MaxQuant.
As a result, 120 putative venom transcripts were confirmed using proteomics. A combination of these
approaches allowed identifying proteins belonging to 43 protein families, among which 15 can be
assigned to snake toxins (Figure 2) (Figures S4–S28).
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Figure 2. (A) Bar chart showing the distribution of Reads Per Kilobase Million (RPKM)
values for all putative venom proteins (PVP) families found in transcriptome; (B) Scatter
plot showing the distribution of riBAQ values of top 43 protein families. The diameter of
the circle is proportional to the number of identified transcripts by quantitative proteomics.
Abbreviations: 3FTx—Three-finger toxin, AAGAB—Alpha/Gamma adaptin binding protein,
ACE—Angiotensinogenase, AChE—Acetylcholinesterase, ANX—Annexin, AP—Aminopeptidase,
APC—Serum amyloid P-component, Butyrophylin—Butyrophylin-like, CAC—Calcyclin,
CFH—Complement factor H, CHI—Chitinase, CNP—C-type natriuretic peptide (Azemiopsin included),
CRISP—cysteine-rich secretory protein, CST—Cystatin, CTS—Cathepsin, EP—Endopeptidase,
HEM—Hemoglobin, HYA—Hyaluronidase, IG—Immunoglobulin, IGFBP—Insulin-like
growth factor-binding, KAZ—kazal serine protease inhibitor, KUN—Kunitz-type serine
protease inhibitor, LAAO—L-amino acid oxidase, LCN—Lipocalin, NUC—5′-nucleotidase,
PDI—Disulfide-isomerase, PLA2—phospholipases A2, PLB—Phospholipase B, Plan-I—Plancitoxin-1
(Deoxyribonuclease-2-alpha), PIN—Peptidyl-prolyl cis-trans isomerase, PLI—Phospholipase
A2 inhibitor, PPT1—Palmitoyl- thioesterase 1, PRDX—Peroxiredoxin, QC—Glutaminyl-peptide
cyclotransferase, SAP—Saposin-A, SF—Siderophilin, SPI—Serpin, SSA—Small serum 2, SVMP—Snake
venom metalloproteinase, SVNGF—Snake-venom nerve growth factor, SVSP—Snake-venom serine
proteinases, svVEGF—Vascular endothelial growth factor, TCTP—Translationally controlled tumor
homolog, TF—Transferrin, vAP—Venom acid phoshatase, vDP—Venom dipeptidyl peptidase 4,
vPA—Venom prothrombin activator, vPDE—Venom phosphodiesterase 1, vPI—Venom peptide
isomerase, vSC—Serine carboxypeptidase, Waprin—Waprin-like.
3.2. Venom-Gland Transcriptome
We estimated the expression level of each transcript by mapping reads against a de novo
transcriptome assembly. As expected, the level of representation of putative venom transcripts
(toxins) is significantly higher than other classes of molecules (Figure 2A). Approximately 63% of total
transcription was accounted for by the coding sequences of putative toxins, and the 54 most abundant
transcripts in the transcriptome encoded putative toxins (Figure 2B).
We grouped all the toxin transcripts into main classes (families) (Figure 3). At the transcriptome
level, the most abundant classes of toxin transcripts are PLA2 and SVSP, followed by the second group
including snake venom nerve growth factor (svNGF), CRISP, C-type natriuretic peptide (CNP, including
azemiopsin), angiotensinogenase (ACE), SVMP, L-amino acid oxidase (LAAO) and snake venom
vascular endothelial growth factor (svVEGF). Such classes of proteins as PLB, venom phosphodiesterase
(vPDE), HYA and 3FTx are significantly less abundant. Thus, the expression pattern of the A. feae
venom gland is typical of viper snakes.
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(A) Expression of toxins and venom proteins (PVP—putative venom transcripts) dominates relative to
other transcripts; (B) The venom-gland transcriptome of A. feae showed high expression and diversity
of snake venom phospholipases A2 and serine proteinases. Expression levels of individual PVP
transcripts are shown with toxin classes coded by color. Abbreviations: ACE—Angiotensinogenase,
CALGL—Calmodulin, CNP—C-type natriuretic peptide (Azemiopsin included), CRISP—Cysteine-rich
secretory protein, HYA—Hyaluronidase, LAAO—L-amino acid oxidase, PLA2—Phospholipases
A2, PLB—Phospholipase B, SVMP—Snake venom metalloproteinase, SVNGF—Snake-venom nerve
growth factor, SVSP—snake-venom serine proteinases, svVEGF—Vascular endothelial growth factor,
vPDE—Venom phosphodiesterase 1.
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However, we detected a number of additional low-abundance toxins in the venom-gland
transcriptome including 3FTxs and acetylcholinesterase not typical for vipers.
3.3. Venom Proteomics/Peptidomics
In this work, both venom proteome and peptidome for Feae’s viper A. feae were analyzed
(Tables S1 and S5). Venom proteome was analyzed by LC–MS/MS after in-solution trypsin proteolysis.
In our study, mass spectrometry analysis of A. feae venom revealed more than one hundred different
proteins, some of them being identified earlier. Thus, PLA2 [11,12] and a plasminogen activator [10]
were isolated from the venom, while the amino acid sequences of CRISP [12], several SVSPs (GenBank:
ART88741.1, ART88740.1, ART88739.1, ART88738.1), three-finger toxin 3FTx-Aze-1 [14], SVNGF [27],
and CNP precursors 1 and 2 [13] were deduced from cloned cDNA sequences. The peptide neurotoxin
azemiopsin was isolated earlier from the A. feae venom as well [15].
Proteomic analysis in addition to the above-mentioned proteins, including those for which amino
acid sequences were deduced from the cDNA, revealed in the venom the presence of LAAO, SVMP,
venom epidermal growth factor, HYA, angiotensinogenase (renin-like aspartic protease), cystatin and
ovomucoid (Kazal-type inhibitor-like protein).
The label-free quantification of venom proteins revealed that the most abundant venom proteins
are SVSPs accounting for 44.8% (mole fraction) of total proteins. They are followed by PLA2s (25.8%),
CRISP (6.0%), LAAO (4.0%), SVMP (3.9%), SVVEGF (3.3%), azemiopsin (bradykinin-potentiating and
C-type natriuretic peptides, 3.0%) and PLB (2.9%). The contents of other venom proteins was less than
one percent: HYA—0.9%, SVNGF—0.4%, cystatin (CST)—0.1%, 3FTx—0.04% and Kazal-type serine
protease inhibitor (Kazal)—0.03%. The toxins present in A. feae venom at the level higher than 1% are
considered in more detail.
3.3.1. Serine Proteases
Using proteomics in A. feae venom, we identified 24 sequences (seven clusters) corresponding to
snake venom serine proteases (SVSPs) (Table S4 and Figure S4). However, the assembled transcripts
are incomplete and are truncated at either the 5′ or 3′ ends. This drawback prevents an adequate
analysis for the classification of SVSPs to certain types. Nevertheless, when considering the alignment,
it is seen that the closest homologs are the previously described proteases from A. feae, which are
secreted trypsin-type proteases (ART88741.1, ART88740.1, ART88739.1, ART88738.1). The identified
sequences include also those homologous to plasminogen activators, one of which was found in this
venom earlier [11], thrombin-like enzymes and homologs of beta-fibrinogenase. All SVSPs from A. feae
venom are homologous to those of other snakes from the Viperidae family. Enzymes homologous to
plasminogen activators and thrombin-like are the most abundant in A. feae venom among SVSPs.
3.3.2. Phospholipases A2
Five clusters PLA2s were found in A. feae venom and 11 sequences we identified by proteomics
(Table S4 and Figure S5A). They are both acidic and basic enzymes from group II subfamily. The most
abundant PLA2s (from about 1 to about 9% of total venom proteins) belong to the enzymatically active
D49 sub-family. The minor PLA2s represent the N49 sub-subfamily (from 0.003 to 2%). We found all
PLA2 subfamilies of N49a, with the exception of N49b previously discovered [12] in A. feae venom from
Zhejiang province (China). In the found sequences, slight differences with reference ones are observed,
which can be explained by genetic polymorphisms. The remaining sequences are intermediate
isoforms of the previously described phospholipases of A. feae venom. New isoforms of basic PLA2s
were also found. The protein sequence TR6913_c96_g4_i4 resembles basic PLA2s, and sequence
TR6913_c96_g4_i6 has homology to the sequence of Crotalus atrox (QBA85153.1) (Figure S5A,B).
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3.3.3. Cysteine-Rich Seceretory Proteins
Only one CRISP was found in the A. feae venom (Figure 4). The CRISP amino acid sequence
determined in this work is very similar to that of Az-CRP determined earlier for A. feae CRISP [12].
The two sequences differ only in two positions, 132 and 236 (Figure 4); Ile and Gln in Az-CRP are
replaced by Thr and Lys, respectively, in the sequence determined in this work.
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3.3.4. L-Amino Acid Oxidase 
LAAO is found in venoms of snakes from different families. Similarly to CRISP, this toxin is 
represented by only one protein in A. feae venom. A. feae LAAO has the highest similarity to that of 
the Okinawa pitviper (or Hime habu), Ovophis okinavensis from the Crotalinae subfamily (Figure S6). 
Figure 4. Amino acid sequence of A. feae CRISPs aligned with sequences of homologous proteins.
TR6925_c0_g1_i2 is the sequence determined in this work. Alignment was generated by MUSCLE
(Here and in all following captions MUSCLE is MUltiple Sequence Comparison by Log-Expectation)
with ClustalX Col ur Scheme: hydrophobic amino acid residues—blue; positively charged—red;
negatively charged—magenta; polar—gre n; cysteines—pink; glycines—orange; prolines—yellow;
aromatic—cyan; unconserved -white.
3.3.4. L-Amino Acid Oxidase
LAAO is found in venoms of snakes from different families. Similarly to CRISP, this toxin is
represented by only one protein in A. feae venom. A. feae LAAO has the highest similarity to that of the
Okinawa pitviper (or Hime habu), Ovophis okinavensis from the Crotalinae subfamily (Figure S6).
3.3.5. Snake Venom Metalloproteinase
In venoms of many species from the Viperidae family, SVMPs are the main components.
For example, in Bothrops atrox venom, SVMPs represent more than half of total venom protein [28].
In A. feae venom, SVMPs account for only 3.9% of total protein and are represented by 16 enzymes
(Figure S7). As in the case of SVSPs, only 5′ or 3′ terminal fragments were assembled, so no full-length
protein sequences were obtained. Analysis of the domain organization (Figure S7B) allowed us
to conclude that A. feae venom contains several isoforms of classical snake venom type III SVMP
(Figure S7).
3.3.6. Snake Venom Vascular Endothelial Growth Factor
In A. feae venom, svVEGF is represented by two proteins which account for 3.3% of total venom
protein (Figure S8).
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3.3.7. Three-Finger Toxins
Among the toxins present in A. feae venom at levels less than 1%, 3FTxs are of special interest.
3FTxs are the main components of venoms from Elapidae snakes. Transcripts of 3FTxs were identified
in transcriptomes of several vipers. However, the neurotoxins were not found in viper venoms so far.
Here, for the first time, we have found the 3FTxs in the venom of a snake from the Viperidae family.
Even though the content of 3FTxs in A. feae venom is as low as 0.04%, there is no doubt about the
presence of these toxins. Five three-finger toxins were found in A. feae venom (Figure 5); according to
their amino acid sequences, they represent so-called basal (commonly known as non-conventional)
toxins containing the fifth disulfide bond in the first loop [29,30]. The recombinant toxin 3FTx-Aze-2
showed the capacity to interact with muscle type and neuronal nicotinic acetylcholine receptors [31].
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3.3.8. Bradykinin-Potentiating Peptides and Azemiopsin 
Azemiopsin is a unique peptide toxin isolated earlier by us from A. feae venom [14]. According 
to the present analysis, its content in the venom is equal to 3.0%. The amino acid sequence of 
azemiopsin was identified previously within C-type natriuretic precursors [13] (Figure 6). It is 
interesting to note that several azemiopsin sequences are present within precursor sequences. 
Moreover, elongated analogs of azemiopsin (M = 2540) with additional N-terminal residues—
SDNWWPKPPHQGPRPPRPRPKP (M = 2627) and ESDNWWPKPPHQGPRPPRPRPKP (M = 2756)—
were identified in the venom (Table S5). When these peptides were fragmented in the mass 
spectrometer, the C-terminal ions remained constant, while for the N-terminal b-ions, corresponding 
mass shifts were observed (Figure S29). 
During isolation of azemiopsin, we found several peptides with molecular masses of 1328.64 (Y-
BPP), 1156.57 (R-BPP) and 1045.5 Da (R-BPP-s). The amino acid sequences of these peptides were 
Figure 5. Three-finger toxins (3FTx). Comparison of amino sequences of A. feae toxins with those
of known 3FTxs. TR2072 c0 g1 i3 is named 3FTx-Aze-2; TR2072 c0 g1 i4—3FTx-Aze-3; TR2072 c0
g1 i2—3FTx-Aze-4; TR14854 c0 g1 i1—3FTx-Aze-5; TR2072 c0 g1 i1—3FTx-Aze-6; TR13523 c0 g1
i1—3FTx-aze-7. Alignment was generated by MUSCLE with ClustalX Colour Scheme: hydrophobic
amino acid residues—blue; positively charged—red; negatively charged—magenta; polar—green;
cysteines—pink; glycines—orange; prolines—yellow; aromatic—cyan; unconserved—white.
3.3.8. Bradykinin-Potentiating Peptides and Azemiopsin
Azemiopsin is a unique peptide toxin isolated earlier by us from A. feae venom [14]. According to
the present analysis, its content in the venom is equal to 3.0%. The amino acid sequence of azemiopsin
was identified previously within C-type natriuretic precursors [13] (Figure 6). It is interesting to note that
several azemiopsin sequences are present within precursor sequences. Moreover, elongated analogs of
azemiopsin (M = 2540) with additional N-terminal residues—SDNWWPKPPHQGPRPPRPRPKP
(M = 2627) and ESDNWWPKPPHQGPRPPRPRPKP (M = 2756)—were identified in the venom
(Table S5). When these peptides were fragmented in the mass spectrometer, the C-terminal ions remained
constant, while for the N-terminal b-ions, corresponding mass shifts were observed (Figure S29).
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3.3.9. Biological Activity of New Bradykinin-Potentiating Peptides 
To study their biological activity, the bradykinin-potentiating peptides Y-BPP and R-BPP were 
prepared by peptide synthesis and purified by reverse-phase chromatography. The potentiating 
effect was investigated in vivo in SD rats; arterial blood pressure was registered. Anesthetized rats 
received peptides through venous catheter, and the arterial catheter was used to record blood 
pressure (BP). Injection of bradykinin at a dose of 7 µg/kg resulted in the BP drop by 27–33% (Figure 8). 
Administration of either Y-BPP or R-BPP 10 min later produced a further small decrease (by about 
10%) in BP and strongly enhanced the effect of bradykinin injected 5 min after BPP (Figure 8). The 
potentiating effect was dose-dependent (Figure 9) and was observed for about half an hour at the 
dose of 300 µg/kg and 1 mg/kg for Y-BPP (Figure 9A,B) and at the dose of 1 mg/kg for R-BPP (Figure 
9C,D). No potentiating effect was detected one hour after BPP administration (Figure 9). 
i re 6. Amino acid sequences of C-type natriuretic precursors deduced from DNA
sequences. Az miopsin—yellow, Y-BPP—lilac, R-BPP and its Lys-analog—light green, putative
shortened R-BPP analog—turquois , putative tripeptide metalloprotein se inhibitor—blu , atrial
natriuretic peptide—red.
During isolation of azemiopsin, we found several peptides with molecular masses of 1328.64
(Y-BPP), 1156.57 (R-BPP) and 1045.5 Da (R-BPP-s). The amino acid sequences of these peptides were
established by de novo MALDI MS/MS sequencing (Figure S30). The determined sequences are shown
in Figure 6. The peptides Y-BPP and R-BPP contain pyroglutamic acid at their N-terminus; the amino
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acid sequence of R-BPP-s corresponds to an N-terminally truncated form of R-BPP. The determined
sequences show homology to some bradykinin-potentiating peptides (Figure 7). However, the
sequences between the two PP repeats are unique for A. feae peptides. It should be mentioned that the
tripeptide sequence QKW is present in the CNP precursor (Figure 6). This tripeptide may represent an
endogenous metalloproteinase inhibitor ZKW (Z = pyroGlu) found in venoms of several Viperidae
species. The C-type natriuretic precursors contain the sequence of C-type natriuretic peptide (Figure 6).
This peptide was also found in the peptidome of A. feae venom (Table S5).
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st t eir i l ical acti it , t e ra i i - te tiati e ti es - a - ere
re are peptide synthesis and purified by reverse-phase chromatography. The potentiati g effect
was investigated in vivo in SD rats; arterial blood pressure was registered. Anesthetized rats received
peptides through ven s catheter, and the arterial catheter was used to record blood pressure (BP).
Injection of bradykini at a dose of 7 µg/kg resulted in the BP drop by 27–33% (Figure 8). Administration
of either Y-BPP r R-BPP 10 min later produced a further small decrease (by about 10%) in BP and
strongly enhanced the effect of bradykinin injected 5 min after BPP (Figure 8). The potentiating effect
was dose-dependent (Figure 9) and was observed for about half an hour at the dose of 300 µg/kg and 1
mg/kg for Y-BPP (Figure 9A,B) and at the dose of 1 mg/kg for R-BPP (Figure 9C,D). No potentiating
effect was det cted one hour after BPP admi istration (Figure 9).
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Figure 9. Percent changes from baseline for mean BPs after injections of bradykinin at a dose of 7
µg/kg in response to bradykinin-potentiating effects of A. feae peptides Y-BPP (A,B) and R-BPP (C,D) at
two doses. # p ≤ 0.05 vs. baseline according to the T-Test for comparing the data of one group before
and after treatment, § p ≤ 0.05 vs. point 1 according to the repeated-measures ANOVA with Dunnett
post-hoc test.
4. iscussion
ze iopinae is regarded as a sister group of the Crotalinae [5,6]. Therefore, it is quite reasonable
that the A. feae veno co position bears a rese blance to those of Crotalinae snakes. Thus, the ain
constituents of Feae’s viper veno are S SPs (44.8 ) and PL 2s (25.8 ), representing about 34 of
veno total protein, although the content of S Ps is fairly s all as co pared to other veno s of
rotalinae snakes [4]. The ost remarkable difference between the Feae’s viper venom and those
of other Crotalids is the presence of the peptide neurotoxin azemiopsin and 3FTxs in . feae veno .
ze iopsin is ho ologous to aglerin fro the sian pit-viper Tropidolae us wagleri veno but in
contrast to aglerin has no disulfide bridge [15,32]. The content of aze iopsin in the veno is lo er
(3 ) than that of aglerin (15 [33] or 38.2 [34]). evertheless, so e neurological sy pto s ere
observed in the victi s of Feae’s viper bite [35], hich ight be caused by aze iopsin. oreover,
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recently it was shown that A. feae venom interacted with fragments representing modified orthosteric
mimotopes of binding region of nicotinic acetylcholine receptors from a diversity of potential preys [36].
This may also indicate the neurotoxicity of the A. feae venom. Indeed, inhibition of the muscle nAChRs
was detected for azemiopsin [15], which later in preclinical studies was shown to be an efficient
myorelaxant [26].
3FTxs are the main components of venoms from Elapidae snakes. They manifest a wide array
of activities ranging from highly specific interactions with some receptors and ion channels to
unspecific damage of cell membranes. 3FTxs were classified into several groups depending on their
amino acid sequences and biological activities [37]. The most abundant groups are neurotoxins
and cytotoxins (cardiotoxins). Cytotoxin-like components were reported in Daboia russelii russelii
venom [38]. Transcripts of 3FTxs were identified in transcriptomes of several vipers, including
A. feae [14]. However, no 3FTx neurotoxins were found in viper venoms so far. In the Feae’s viper
venom, we have identified several 3FTxs (Figure 7); all these toxins contain the fifth disulfide bridge in
the loop I and thus belong to so-called basal or non-conventional toxins [29,30]. Toxins of this group,
similarly to α-neurotoxins, interact with some types of nicotinic acetylcholine receptors [39,40] and
bind to muscarinic acetylcholine receptors as well [41,42]. It should be mentioned that the sequences
of 3FTxs determined in this work are different from 3FTx-Aze-1 [14] described earlier. The differences
between the published sequence 3FTx-Aze-1 and our sequence 3FTx-Aze-2 are not very big, including
only four substitutions at positions 42, 63, 68 and 69, and may be explained by individual venom
variations (Figure 5), while the other toxin amino acid identified in this work differs more strongly
from that of 3FTx-Aze-1. The sequences of A. feae 3FTxs are distinguished by the number of amino acid
residues between invariant cysteine residues. In addition, 3FTx-Aze-4 has an extended C-terminal tail,
which makes it similar to long-type α-neurotoxins from elapid venoms. Based on the results obtained,
it can be concluded that the A. feae 3FTxs are quite remarkable. The amino acid sequences of some
A. feae 3FTxs have similarities with sequences of toxins from Colubridae. Interestingly, heterogeneity
in sequences is observed within one species, and some of the sequences are closer to those from
Viperidae and some from Colubridae. The first step to investigate the biological activity of A. feae
three-finger toxins is our recent work, where the gene encoding the sequence of 3FTx-Aze-2 (Figure 5)
was synthesized, expressed in Escherichia. coli, and the biological activity studies showed that the
heterologously expressed toxin inhibited nicotinic acetylcholine receptors of both muscle and neuronal
types [31].
It should be noted that the important components of Crotalidae venoms are
bradykinin-potentiating peptides (BPP). BPPs are produced in venom glands by processing
long precursor proteins including as a rule several sequences of BPP and natriuretic peptide.
During mass-spectrometric analysis of A. feae venom, we have found two peptides, Y-BPP and
R-BPP, with amino acid sequences homologous to BPPs (Figure 7). The synthetic BPPs showed
bradykinin-potentiating effects (Figures 8 and 9). Analysis of transcriptomic data revealed a nucleotide
sequence encoding a polypeptide containing several azemiopsin sequences as well as sequences of
both Y-BPP and R-BPP (Figure 5). We have not obtained precursors with sequence length similar to the
ones determined before [13]; however, the shorter fragments fit well to the long precursor. It should
be mentioned that the sequences of one BPP are different; the lysine residue in the long precursor
is replaced by arginine in the sequence of R-BPP (Figure 6). The tripeptide fragment QKW is also
found in the sequences of precursors. The tripeptide ZKW characteristic to Viperidae venoms is an
endogenous inhibitor of metalloproteinases [43,44]. Usually, several QKW repeats have been found in
the CNP precursors; however, only one is found in sequence from A. feae.
In addition, if we fully cover the repertoire of toxins from what we found only in the form of
transcripts, it turns out that A. feae retained a wider range of toxins from the common ancestor of
Viperidae. Apparently, the common ancestor had a much wider arsenal of toxins. It is logical to
assume that retaining a wider range of toxins is due to the absence of strict selection in the habitat of
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A. feae; in other Viperidae, the selection was apparently due to specialization in prey and a change in
living conditions.
For the Viperidae, an origin in Asia was presumed, and for the Crotalinae (and Azemiops), the
origin was firmly placed in Asia [5,6]. It can be assumed that A. feae is a relic (“ancient old-timer”) whose
habitat was stable enough to leave the entire toxin repertoire or at least part of it almost unchanged.
Various assumptions can be made about the presence of transcripts, but the lack of protein would
indicate that this is just a blank transcription. Again, the lack of selection minimizes their divergence.
The found unique peptides may be just a new type of adaptation and a unique feature of A. feae or
further development of toxins inherited from an ancient ancestor.
For biological activity studies, Y-BPP and R-BPP were prepared by solid phase synthesis. Studies on
SD rats revealed that both peptides dose-dependently potentiated the activity of bradykinin. At 1
mg/kg, the peptides increased the bradykinin effects by 30% (Figure 9B,D). This value is similar to the
ones observed for some BPPs from Bothrops venoms [45]. While Y-BPP has some structural similarity
to BPPs earlier described, for example to BPPB from Agkistrodon blomhofii (Figure 7), the sequence of
R-BPP is unique. Thus, we have found a BPP with a new structural motif.
5. Conclusions
We have described the comprehensive venom-gland transcriptomic and quantitative proteomic
venom characterization of A. feae viper. The proteomic analysis revealed the presence of 120
unique proteins, serine proteinases and phospholipases A2 being the most abundant. In total,
toxins representing 14 families were identified, among which bradykinin-potentiating peptides
with unique amino acid sequence features were found and shown to possess biological activity
in vivo. The proteomic analysis also revealed three-finger toxins which belong to the group of
non-conventional toxins possessing neurotoxic activity. This is the first indication of the presence of
three-finger neurotoxins in viper venom. The transcriptomic analysis of the venom gland by Illumina
next-generation sequencing revealed 206 putative venom transcripts. Together, the study unveiled the
venom proteome and venom gland transciptome of A. feae, which in general resemble those of snakes
from the Viperidae family. However, new toxins not found earlier in viper venom and including
three-finger toxins and unusual bradykinin-potentiating peptides were discovered.
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